Bruno Crestani

Jun 27, 2024 | bmjopenrespres.bmj.com | Lisa Lancaster |Bruno Crestani |Paul Hernandez |Yoshikazu Inoue

Interstitial lung disease Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

May 16, 2024 | erj.ersjournals.com | Bruno Crestani

FootnotesConflict of interest: B.

Apr 4, 2024 | hal.science | Vincent Cottin |Philippe Bonniaud |Jacques Cadranel |Bruno Crestani

Article Dans Une Revue Respiratory Medicine and Research Année : 2023 French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update.

Jan 4, 2024 | erj.ersjournals.com | Bruno Crestani

FootnotesConflict of interest: D.G. Helou reports grants or contracts from Agence Nationale de la Recherche and Inserm Transfert, outside the submitted work. B.

Sep 1, 2023 | mdpi.com | Bruno Crestani |Doumet Georges Helou |Deepak Pokhreal |Doumet Georges

1. Introduction 1.1. Generalities about IPF IPF is a fatal lung disease characterized by irreversible fibrosis of the lungs, leading to increased cough, dyspnea, and decreased quality of life. It is seen among middle-aged and elderly adults [1,2]. The incidence of IPF ranges from 0.09 to 1.30 per 10,000 persons globally, and the prevalence of the disease ranges from 0.33 to 4.51 per 10,000 persons [1].